Summary & Overview
HCPCS J0209: Sodium Thiosulfate Injection, 100 mg
HCPCS Level II code J0209 denotes an injection of sodium thiosulfate (hope), 100 mg, used when billing for parenteral administration of this medication across outpatient settings. Nationally, drug-specific HCPCS codes like J0209 matter because they affect drug reimbursement, billing compliance, and access to specialty infusions. This publication examines payer coverage for this code and provides clinical and billing context relevant to facilities and clinicians.
Key payers analyzed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of typical sites of service for this injectable medication, common modifiers associated with HCPCS drug administration, and what to expect in payer interactions. The report summarizes benchmark coverage patterns, common billing practices, and policy considerations affecting injectable drug claims.
The content highlights where to find billing guidance, the role of HCPCS Level II coding for medication-specific billing, and operational implications for infusion centers and outpatient clinics. Data not available in the input will be noted where applicable. This national-focused summary is intended to inform billing staff, revenue cycle managers, and clinical administrators about the practical significance of HCPCS Level II code J0209.
Billing Code Overview
HCPCS Level II code J0209 represents an injection of sodium thiosulfate (hope), 100 mg. This code describes a parenteral medication product administered by injection. The service type is drug administration / injectable medication. The typical site of service for billing this HCPCS Level II code is an outpatient infusion or injection setting, such as a hospital outpatient department, ambulatory infusion center, clinic, or physician office.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with calciphylaxis, cisplatin-induced ototoxicity mitigation, or severe calcific vascular disease receiving IV sodium thiosulfate. The patient is usually referred by nephrology, dermatology, oncology, or vascular surgery. Preparation includes verification of J0209 for sodium thiosulfate, review of allergies, baseline vital signs and laboratory studies (electrolytes, renal function), and informed consent for off-label or high-cost therapy when applicable. Administration commonly occurs in an outpatient infusion center, dialysis unit, or inpatient hospital bed. The medication is drawn and prepared by pharmacy or certified infusion staff, then administered via peripheral or central intravenous access over the prescribed duration, with monitoring for hypotension, metabolic disturbances, or allergic reaction. Post-infusion observation includes repeat vital signs, assessment for infusion-related reactions, and documentation of lot number and dose using J0209. Billing includes the HCPCS code J0209 reported per 100 mg unit, with applicable modifier(s) to indicate services such as institutional versus professional component, administration circumstances, or discarded medication portions.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |